{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:49:17Z","timestamp":1787003357238,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T00:00:00Z","timestamp":1508284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T00:00:00Z","timestamp":1508284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To investigate the efficacy and safety of Tocilizumab (TCZ) in patients with refractory adult-onset Still\u2019s disease (AOSD). We enrolled 8 female patients from October 2013 to July 2014. All patients fulfilled Japan\u2019s Yamaguch AOSD classification and recognized as refractory AOSD. All Patients received TCZ treatment 4\u20138\u2009mg\/kg every 4 weeks. Evaluation of efficacy was conducted after 3 months and 6 months, including clinical manifestations of AOSD patients, improvement of inflammatory markers as well as glucocorticoids dosage adjustments. Treatment-related adverse events were also recorded. Patients treated with Tocilizumab with average age 41.1 years old, the average disease duration 23.6 months. Two patients drop off due to infusion side effects. Others were followed at least 6 months. After 3 months of follow-up, remission rates of fever, arthritis and rashes from 8 patients were 87.5%, 100% and 87.5%. White blood cell counts, erythrocyte sedimentation rate, C-reactive protein and ferritin levels were decreased (P\u2009&lt;\u20090.01) significantly compared to treatment before. Furthermore, the average dose of prednisone was reduced from 51.7\u2009\u00b1\u200938.4\u2009mg\/d to 12.9\u2009\u00b1\u20097.7\u2009mg\/d (P\u2009&lt;\u20090.01). Our findings suggest that tocilizumab could alleviate the clinical manifestations of refractory AOSD rapidly and efficiently.<\/jats:p>","DOI":"10.1038\/s41598-017-13639-y","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T09:17:44Z","timestamp":1507799864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still\u2019s Disease"],"prefix":"10.1038","volume":"7","author":[{"given":"Ting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengde","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,18]]},"reference":[{"key":"13639_CR1","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi, M. Preliminary criteria for classification of adult Still\u2019s disease. Journal of Rheumatology. 19, 424\u2013430 (1992).","journal-title":"Journal of Rheumatology."},{"key":"13639_CR2","doi-asserted-by":"crossref","unstructured":"Bruno Fautrel. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 22, 773\u2013792 (2008).","DOI":"10.1016\/j.berh.2008.08.006"},{"issue":"Suppl 3","key":"13639_CR3","doi-asserted-by":"crossref","first-page":"iii55","DOI":"10.1136\/ard.60.90003.iii55","volume":"60","author":"HG Kraetsch","year":"2001","unstructured":"Kraetsch, H. G., Antoni, C. & Kalden, J. R. et al. Successful treatment of a small cohort of patients with adult onset of Still\u2019s disease with infliximab: first experiences. Annals of the Rheumatic Diseases. 60(Suppl 3), iii55\u201357 (2001).","journal-title":"Annals of the Rheumatic Diseases."},{"key":"13639_CR4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/art.10231","volume":"46","author":"ME Husni","year":"2002","unstructured":"Husni, M. E., Maier, A. L. & Mease, P. J. et al. Etanercept in the treatment of adult patients with Still\u2019s disease. Arthritis and Rheumatism. 46, 1171\u20131176 (2002).","journal-title":"Arthritis and Rheumatism."},{"key":"13639_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/ard.2004.024026","volume":"64","author":"B Fautrel","year":"2005","unstructured":"Fautrel, B., Sibilia, J. & Mariette, X. et al. Tumour necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases. Annals of the Rheumatic Diseases. 64, 262\u2013266 (2005).","journal-title":"Annals of the Rheumatic Diseases."},{"key":"13639_CR6","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/art.10620","volume":"46","author":"M Iwamoto","year":"2002","unstructured":"Iwamoto, M., Nara, H. & Hirata, D. et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still\u2019s disease. Arthritis and Rheumatism. 46, 3388\u20133389 (2002).","journal-title":"Arthritis and Rheumatism."},{"key":"13639_CR7","first-page":"141","volume":"32","author":"Hde Boysson","year":"2013","unstructured":"Boysson, Hde, F\u00e9vrier, J. & Nicolle, A. et al. Tocilizumab in the treatment of the adult-onset Still\u2019s disease:current clinical evidence.Clin Rheumatol. 32, 141\u2013147 (2013).","journal-title":"Tocilizumab in the treatment of the adult-onset Still\u2019s disease:current clinical evidence.Clin Rheumatol."},{"key":"13639_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/ard.30.2.121","volume":"30","author":"EG Bywaters","year":"1971","unstructured":"Bywaters, E. G. Still\u2019s disease in the adult. Annals of the Rheumatic Diseases. 30, 121\u2013133 (1971).","journal-title":"Annals of the Rheumatic Diseases."},{"key":"13639_CR9","first-page":"1058","volume":"17","author":"A Ohta","year":"1990","unstructured":"Ohta, A., Yamaguchi, M. & Tsunematsu, T. et al. Adult Still\u2019s disease: a multicenter survey of Japanese patients. Journal of Rheumatology. 17, 1058\u20131063 (1990).","journal-title":"Journal of Rheumatology."},{"key":"13639_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","volume":"81","author":"B Fautrel","year":"2002","unstructured":"Fautrel, B., Zing, E. & Golmard, J. L. Proposal for a new set of classification criteria for adult onset Still disease. Medicine (Baltimore). 81, 194\u2013200 (2002).","journal-title":"Medicine (Baltimore)."},{"key":"13639_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MD.0000000000000021","volume":"93","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin, M., Maucort-Boulch, D. & Hot, A. et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 93, 91\u201399 (2014).","journal-title":"Medicine (Baltimore)."},{"key":"13639_CR12","first-page":"2189","volume":"31","author":"DY Chen","year":"2004","unstructured":"Chen, D. Y., Lan, J. L., Lin, F. J. & Hsieh, T. Y. Proin ammatory cytokine pro les in sera and pathological tissues of patients with active untreated adult onset Still\u2019s disease. J Rheumatol. 31, 2189\u20132198 (2004).","journal-title":"J Rheumatol."},{"key":"13639_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/acr.21901","volume":"65","author":"C Giampietro","year":"2013","unstructured":"Giampietro, C., Ridene, M. & Lequerre, T. et al. Anakinra in adult-onset Still\u2019s disease: Long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 65, 822\u2013826 (2013).","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"13639_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3899\/jrheum.130575","volume":"41","author":"R Priori","year":"2014","unstructured":"Priori, R., Colafrancesco, S. & Alessandri, C. et al. Interleukin 18: A biomarker for di erential diagnosis between adult-onset Still\u2019s disease and sepsis. J Rheumatol. 41, 1118\u20131123 (2014).","journal-title":"J Rheumatol."},{"key":"13639_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/ard.2004.024026","volume":"64","author":"B Fautrel","year":"2005","unstructured":"Fautrel, B., Sibilia, J., Mariette, X. & Combe, B. Tumour necrosis factor a blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases. Ann Rheum Dis. 64, 262\u2013266 (2005).","journal-title":"Ann Rheum Dis."},{"key":"13639_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001554","volume":"94","author":"F Ortiz-Sanjua\u0301n","year":"2015","unstructured":"Ortiz-Sanjua\u0301n, F., Blanco, R. & Riancho-Zarrabeitia, L. et al. Efficacy of anakinra in refractory adult-onset Still\u2019s disease: Multicenter study of 41 patients and literature review. Medicine (Baltimore). 94, e1554 (2015).","journal-title":"Medicine (Baltimore)."},{"key":"13639_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/acr.20319","volume":"63","author":"X Pue\u0301chal","year":"2011","unstructured":"Pue\u0301chal, X., DeBandt, M. & Berthelot, J. M. et al. Tocilizumab in refractory adult Still\u2019s disease. Arthritis Care Res (Hoboken). 63, 155\u2013159 (2011).","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"13639_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10067-003-0775-5","volume":"23","author":"A Kokkinos","year":"2004","unstructured":"Kokkinos, A., Iliopoulos, A. & Greka, P. et al. Successful treatment of refractory adult-onset Still\u2019s disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol. 23, 45\u201349 (2004).","journal-title":"Clin Rheumatol."},{"key":"13639_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.semarthrit.2012.03.004","volume":"42","author":"A Kontzias","year":"2015","unstructured":"Kontzias, A. & Efthimiou, P. The use of canakinumab, a novel IL-1b long-acting inhibitor, in refractory adult-onset Still\u2019s disease. Semin Arthritis Rheum. 42, 201\u2013205 (2015).","journal-title":"Semin Arthritis Rheum."},{"key":"13639_CR20","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1055\/s-2004-826865","volume":"129","author":"C Dechant","year":"2004","unstructured":"Dechant, C., Schauenberg, P. & Antoni, C. E. et al. Longterm outcome of TNF blockade in adult-onset Still\u2019s disease. Dtsch Med Wochenschr. 129, 1308\u20131312 (2004).","journal-title":"Dtsch Med Wochenschr."},{"key":"13639_CR21","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-010-0348-9","volume":"21","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi, M., Takahashi, Y. & Yamashita, H. et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 21, 92ati (2011).","journal-title":"Mod Rheumatol."}],"updated-by":[{"DOI":"10.1038\/s41598-018-36662-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13639-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13639-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13639-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T07:11:33Z","timestamp":1750921893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13639-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,18]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["13639"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-13639-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,18]]},"assertion":[{"value":"6 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13477"}}